Zevra Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ZVRA Nasdaq 2834 www.zevra.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zevra Therapeutics, Inc.

Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Jun 11th, 2026 6:30 am
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Jun 9th, 2026 3:19 pm
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Jun 9th, 2026 10:50 am
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - Jun 8th, 2026 12:19 pm
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 - Jun 8th, 2026 10:25 am
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA - Jun 8th, 2026 5:30 am
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 29th, 2026 2:30 pm
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear - May 13th, 2026 5:22 am
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference - May 12th, 2026 5:30 am
Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - May 9th, 2026 8:15 am
Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge? - May 7th, 2026 12:19 pm
Zevra Therapeutics Q1 Earnings Call Highlights - May 7th, 2026 4:07 am
Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary - May 6th, 2026 6:31 pm
Zevra (ZVRA) Q1 2026 Earnings Call Transcript - May 6th, 2026 4:45 pm
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates - May 6th, 2026 4:30 pm
Zevra Reports First Quarter 2026 Financial Results and Corporate Update - May 6th, 2026 2:05 pm
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 7:15 am
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call - Apr 22nd, 2026 5:30 am
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? - Mar 23rd, 2026 7:07 pm
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Mar 22nd, 2026 7:05 pm